RxDoctor Payments Data

Michael Thorpy, MD

Neurology · Bronx, NYNPI 1134204456

Payments from drug & device makers

$721,662in general payments, 2019–2025

Across 420 payments — averaging $1718.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$387K
  • Takeda Pharmaceuticals U.S.A., Inc.$216K
  • Harmony Biosciences LLC$41K
  • Eisai Inc.$31K
  • Avadel CNS Pharmaceuticals, LLC$22K
  • Axsome Therapeutics, Inc.$9K
  • plus $16K from 7 others
$6,736in research payments, 2019–2025

Across 26 payments — averaging $259.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$5K
  • Harmony Biosciences LLC$2K

What the payments were for

  • Consulting fees$189,14882%
  • Speaking & faculty fees$18,4748%
  • Travel & lodging$18,8638%
  • Food & beverage$5,1602%
  • Education$2300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$721,662 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$19,224
Medicare patients
73
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate39$719,396
Sodium Oxybate19$313,192
SunosiSolriamfetol Hcl45$53,894
NeuproRotigotine13$10,439
QuviviqDaridorexant Hcl12$5,673
Methylphenidate Hcl13$2,832
Modafinil26$1,064
Armodafinil31$833
Clonazepam21$548
Amitriptyline Hcl25$388
Zolpidem Tartrate69$311
Venlafaxine Hcl ErVenlafaxine Hcl37$237
Escitalopram Oxalate13$113
Zolpidem Tartrate ErZolpidem Tartrate12$92
Gabapentin15$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Axsome Therapeutics, Inc.Sunosi$9,311$53,89445 claims
Idorsia Pharmaceuticals US IncQuviviq$4,754$5,67312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.

Other neurology in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →